Vir Biotechnology, Inc.
VIR
$5.09
-$0.325-6.01%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -94.62% | -26.29% | -9.81% | -19.02% | -10.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -94.62% | -26.29% | -9.81% | -19.02% | -10.45% |
| Cost of Revenue | 19.36% | -16.53% | 34.58% | -37.44% | -38.24% |
| Gross Profit | -171.79% | 14.70% | -35.40% | 37.87% | 56.36% |
| SG&A Expenses | -34.08% | -35.22% | -37.11% | -33.50% | -22.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.97% | -21.75% | 18.80% | -36.60% | -34.64% |
| Operating Income | -76.51% | 21.16% | -19.21% | 36.92% | 45.26% |
| Income Before Tax | -86.08% | 13.32% | -28.16% | 29.21% | 54.61% |
| Income Tax Expenses | -94.20% | 98.20% | 105.51% | 46.91% | 112.37% |
| Earnings from Continuing Operations | -85.31% | 9.82% | -30.78% | 28.95% | 53.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -85.31% | 9.82% | -30.78% | 28.95% | 53.67% |
| EBIT | -76.51% | 21.16% | -19.21% | 36.92% | 45.26% |
| EBITDA | -83.42% | 20.65% | -20.65% | 37.54% | 46.30% |
| EPS Basic | -82.36% | 11.27% | -28.52% | 30.09% | 54.27% |
| Normalized Basic EPS | -116.23% | 21.09% | -23.62% | 40.04% | 56.34% |
| EPS Diluted | -82.36% | 11.72% | -28.52% | 30.09% | 54.27% |
| Normalized Diluted EPS | -116.23% | 21.09% | -23.62% | 40.04% | 56.34% |
| Average Basic Shares Outstanding | 1.62% | 1.63% | 1.76% | 1.62% | 1.29% |
| Average Diluted Shares Outstanding | 1.62% | 1.63% | 1.76% | 1.62% | 1.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |